Table 1.
Variable | Study population (n = 20) |
---|---|
Age (years), median [25th–75th percentiles] | 66.2 [61.2–70.8] |
Female sex, n (%) | 11 (55) |
Body Mass Index (kg/m2), mean ± SD | 30.9 ± 5.6 |
Cardiovascular risk factors | |
Hypertension, n (%) | 20 (100) |
Diabetes, n (%) | 2 (10) |
Dyslipidemia, n (%) | 8 (40) |
Smoking | |
Ever-smoking, n (%) | 4 (20) |
Current smoking, n (%) | 1 (5) |
Family history of ischemic heart disease, n (%) | 4 (20) |
Arrhythmia-related history | |
Atrial fibrillation | |
Paroxysmal atrial fibrillation, n (%) | 18 (90) |
Persistent atrial fibrillation, n (%) | 2 (10) |
Cardioversion | |
Electrical cardioversion, n (%) | 10 (50) |
Chemical cardioversion, n (%) | 2 (10) |
Flutter ablation, n (%) | 1 (5) |
Pulmonic vein isolation, n (%) | 4 (20) |
MAZE procedure, n (%) | 0 (0) |
Left Atrial Appendage Occluder, n (%) | 2 (10) |
Prescribed medication | |
Antiarrhythmic drugs | |
Defined daily dosages, median [25th–75th percentiles] | 1.0 [0.5–1.3] |
Number of drugs, median [25th–75th percentiles] | 1.0 [1.0–1.3] |
Antihypertensive drugs | |
Defined daily dosages, mean ± SD | 2.7 ± 1.6 |
Number of drugs, median [25th–75th percentile] | 2.0 [2.0–3.0] |
Blood pressure | |
Mean 24-h ambulatory BP (mmHg), mean ± SD | 129.5/77.3 ± 15.5/9.3 |
Daytime ambulatory BP (mmHg), mean ± SD | 132.3/79.5 ± 15.8/9.7 |
Nighttime ambulatory BP (mmHg), mean ± SD | 120.7/70.1 ± 17.4/10.4 |
Office BP (mmHg), mean ± SD | 153.8/87.5 ± 15.2/10.4 |
Quality-of-life | |
Overall AFEQT score (range 0–100), mean ± SD | 66.4 ± 15.0 |
AFEQT Atrial Fibrillation Effect on QualiTy-of-Life, BP blood pressure, EHRA European Heart Rhythm Association, SD standard deviation